CAS Number86386-73-4
Synonyms2-(2,4-Difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)-2-propanol; triflucan; Flunazol; Apo Fluconazole; FluMycon; α-(2,4-Difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; Zonal; 2-(2,4-Difluorphenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol; Apo-Fluconazole; 2,4-Difluoro-a,a-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl Alcohol; Diflucan; Zoltec; Difluean; 2-(2,4-Difluorphenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; a-(2,4-Difluorophenyl)-a-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; 2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol; Fluconazole; EINECS 200-659-6; Diflazon; MFCD00274549; Flusol; Elazor; Flucostat; Fluconal; 2-(2,4-DIFLUOROPHENYL)-1,3-BIS-(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
Molecular FormulaC13H12F2N6O
Molecular Weight306.27
Purity≥98 (HPLC)%
Density1.5±0.1 g/cm3
Boiling Point579.8±60.0 °C at 760 mmHg
Melting Point138-140°C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 86386-73-4 |
| Catalog No. | 2A-9010544 |
| Chinese Name | 氟康唑 |
| Synonyms | 2-(2,4-Difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)-2-propanol; triflucan; Flunazol; Apo Fluconazole; FluMycon; α-(2,4-Difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; Zonal; 2-(2,4-Difluorphenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol; Apo-Fluconazole; 2,4-Difluoro-a,a-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl Alcohol; Diflucan; Zoltec; Difluean; 2-(2,4-Difluorphenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; a-(2,4-Difluorophenyl)-a-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; 2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol; Fluconazole; EINECS 200-659-6; Diflazon; MFCD00274549; Flusol; Elazor; Flucostat; Fluconal; 2-(2,4-DIFLUOROPHENYL)-1,3-BIS-(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL |
| Molecular Formula | C13H12F2N6O |
| Molecular Weight | 306.27 |
| Purity | ≥98 (HPLC) |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 579.8±60.0 °C at 760 mmHg |
| Melting Point | 138-140°C |
| Appearance | powder |
| Water Solubility | DMSO: 5 mg/mL |
| Storage Condition | Closed, cool, dry place |
| Application | Fluconazole is an antifungal compound that can be used to treat superficial and systemic fungal infections. |
| HTC | 2933990090 |
| PubChem ID | 24724485 |
| MDL Number | MFCD00274549 |
| SMILES | FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1 |
| InChI | 1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 |
| InChI Key | RFHAOTPXVQNOHP-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/10544_1_86386_73_4.pdf |
| Bioactivity | Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.Target: AntifungalFluconazole is a triazole antifungal intended for oral treatment of superficial and systemic mycoses. In tests done in standard mycological media, the compound had minimal inhibitory concentrations against pathogenic Candida species that were usually in excess of 100 mg/l. Fluconazole inhibited branching and hyphal development in C. albicans at concentrations as low as 10(-6) M (0.3 mg/l), but miconazole and ketoconazole were still active in these tests at concentrations 100 times lower than this [1]. Oral fluconazole was not associated with a significantly increased risk of birth defects overall or of 14 of the 15 specific birth defects of previous concern. Fluconazole exposure may confer an increased risk of tetralogy of Fallot [2]. Fluconazole is predicted to be ineffective against Cryptococcus gattii in the koala as a sole therapeutic agent administered at 10 mg/kg p.o. every 12 h [3].Clinical indications: Balanitis; Candida infection; Cryptococcus infection; Cryptococcus neoformans meningitis; Dermatomycosis; Female genital tract infection; Fungal infection; Fungal respiratory tract infection; Fungal urinary tract infection; Prophylaxis; Tinea capitis; Tinea corporis; Tinea cruris; Tinea pedis .Toxicity: Symptoms of overdose include hallucinations and paranoid behavior. Related Catalog Signaling Pathways >> Anti-infection >> Fungal Research Areas >> Infection References [1]. Odds, F.C., S.L. Cheesman, and A.B. Abbott, Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother, 1986. 18(4): p. 473-8. [2]. Molgaard-Nielsen, D., B. Pasternak, and A. Hviid, Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med, 2013. 369(9): p. 830-9. [3]. Black, L.A., et al., Pharmacokinetics of fluconazole following intravenous and oral administration to koalas (Phascolarctos cinereus). J Vet Pharmacol Ther, 2013. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 579.8±60.0 °C at 760 mmHg Melting Point 138-140°C Molecular Formula C13H12F2N6O Molecular Weight 306.271 Flash Point 304.4±32.9 °C Exact Mass 306.104065 PSA 81.65000 LogP 0.50 Vapour Pressure 0.0±1.7 mmHg at 25°C Index of Refraction 1.663 InChIKey RFHAOTPXVQNOHP-UHFFFAOYSA-N SMILES OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F Storage condition −20°C Water Solubility DMSO: 5 mg/mL |
| Use of | Properties Articles154 Name fluconazole Synonym More Synonyms Fluconazole Biological Activity Related Catalog Signaling Pathways >> Anti-infection >> Fungal Research Areas >> Infection References [1]. Odds, F.C., S.L. Cheesman, and A.B. Abbott, Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother, 1986. 18(4): p. 473-8. [2]. Molgaard-Nielsen, D., B. Pasternak, and A. Hviid, Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med, 2013. 369(9): p. 830-9. [3]. Black, L.A., et al., Pharmacokinetics of fluconazole following intravenous and oral administration to koalas (Phascolarctos cinereus). J Vet Pharmacol Ther, 2013. Chemical & Physical Properties Molecular Formula C13H12F2N6O Exact Mass 306.104065 PSA 81.65000 Index of Refraction 1.663 InChIKey RFHAOTPXVQNOHP-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Etoricoxib | 202409-33-4 | 2A-9010426 |
| Exemestane | 107868-30-4 | 2A-9010439 |
| Febuxostat | 144060-53-7 | 2A-9010455 |
| Felodipine HCL | 72509-76-3 | 2A-9010457 |
| Fentanyl | 437-38-7 | 2A-9010495 |
| Fluoxetine HCl; Fluoxetine hydrochloride | 56296-78-7 | 2A-9010571 |
| Fluphenazine | 69-23-8 | 2A-9010573 |
| Fluphenazine enanthate | 2A-301657 | 2A-9010574 |
| Fluvastatin | 93957-54-1 | 2A-9010592 |
| Fluvastatin sodium | 93957-55-2 | 2A-9010593 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS